Institutional Portfolio Favorite in Spotlight: Seattle Genetics, Inc. (NASDAQ:SGEN)

Marco Green
October 18, 2017

Therefore 38% are positive. SGEN traded on a high for the day of 63.19 with a corresponding low of 61.31.The day's high marked a slight increase on the previous day's close which saw SGEN finish the day's trading at 61.31.

Seattle Genetics, Inc. has a beta of 2.39 meaning it is higher in volatility than the market as a whole that has a beta of 1. GlaxoSmithKline had 22 analyst reports since September 8, 2015 according to SRatingsIntel. Goldman Sachs upgraded Seattle Genetics, Inc. (NASDAQ:SGEN). Investors holds 2.72 million shares or 0.19% of its portfolio. The firm earned "Neutral" rating on Monday, October 12 by JP Morgan. (NASDAQ:SGEN) rating on Friday, August 14. The firm has "Neutral" rating given on Wednesday, July 5 by Citigroup. Bank of America downgraded the stock to "Underperform" rating in Friday, February 10 report. RBC Capital Markets maintained the stock with "Outperform" rating in Monday, October 10 report. Zacks Investment Research downgraded Seattle Genetics from a buy rating to a hold rating in a research note on Monday. The rating was maintained by Jefferies on Tuesday, September 12 with "Buy". The firm earned "Neutral" rating on Wednesday, April 5 by BNP Paribas. The stock of Seattle Genetics, Inc. It has a 169.62 P/E ratio. As of December 31, 2016, the Company's six subsidiary banks were located primarily in suburban or semi-rural geographic markets throughout a five-state region (Pennsylvania, Delaware, Maryland, New Jersey and Virginia). About 338,601 shares traded. United States Steel Corporation (NYSE:X) has risen 45.54% since October 17, 2016 and is uptrending.

Ratings analysis reveals 33% of Fulton Fincl's analysts are positive. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. Over the course of the a year ago SGEN has set a 52-week high of $75.36 while the corresponding low set was $45.31.

Price targets show what analysts believes a stock will be worth at the end of a certain time period. The stock is performing 134.71% year to date.

Analysts await Fulton Financial Corp (NASDAQ:FULT) to report earnings on October, 17. The stock declined 0.56% or $0.23 reaching $40.79 per share. Next quarter's EPS is estimated at $-0.45 with next year's EPS projected to be $-1.22. The company now has an average rating of "Hold" and an average price target of $60.38. Aperio Group LLC now owns 31,693 shares of the biotechnology company's stock valued at $1,640,000 after acquiring an additional 91 shares during the last quarter. Dividends are mostly given in terms of cash payments, property or as shares of stock. Analysts have a mean recommendation of 2.60 on this stock.

12/29/2016 - Seattle Genetics, Inc. had its "neutral" rating reiterated by analysts at Cantor Fitzgerald. (NASDAQ:SGEN). Renaissance Lc accumulated 6,613 shares.

Seattle Genetics, Inc. (SGEN) stock price is sinking -0.17% to $62.89.

Seattle Genetics, a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The Company is involved in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. It now has negative earnings. The company has market cap of $4.70 billion. Its down 0.20, from 1.5 in 2017Q1. Analysts on average have given a price target of $60.17 to Seattle Genetics, Inc. stock. 48 funds opened positions while 89 raised stakes. Short interest decreased 137,269 over that period. Susquehanna Gp Limited Liability Partnership owns 0% invested in Seattle Genetics, Inc.

But it's not just buying activity that is creating investor interest in SGEN; over the last several weeks, several insiders have sold shares. Millennium Ltd Llc reported 148,091 shares. (SGEN) is 19.39 percent while its Performance (Week) is 9.55 percent and Performance (month) is at 18.55 percent. Nationwide Fund Advsr stated it has 0% in Seattle Genetics, Inc. (NASDAQ:SGEN) for 100,000 shares. Bancorp Of Montreal Can reported 1,767 shares stake. The option since executed brings Siegall ownership to 687146 shares.

Other reports by Click Lancashire

Discuss This Article